{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:43:57Z","timestamp":1794069837364,"version":"4.8.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SMA Type 1 is the most severe form of spinal muscular atrophy with early symptom onset, limited motor development, and poor prognosis. Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4\u202fyears.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, non-interventional study included 310 patients with genetically confirmed spinal muscular atrophy at 24 pediatric neurology centers in Turkey. Patients treated with nusinersen were divided into five age-based cohorts at treatment initiation: Cohort A (0\u20133\u202fmonths), Cohort B (4\u20136\u202fmonths), Cohort C (7\u201312\u202fmonths), Cohort D (13\u201324\u202fmonths), and Cohort E (&amp;gt;24\u202fmonths). Efficacy was assessed using the CHOP-INTEND and WHO Motor Milestone Scale. This study also analyzed the respiratory support needs, gastrostomy requirements, and mortality rates across cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients treated before 12\u202fmonths of age showed the most significant improvements in motor milestones, with 58.7% of Cohort A achieving independent sitting. CHOP-INTEND scores increased notably in all cohorts, with the largest improvement observed in Cohort A (93.5%). Ventilator and gastrostomy requirements decreased in the early treated cohorts. Adverse events were rare, with one discontinuation due to hydrocephalus. The overall mortality rate was 21.3%, with most of the deaths occurring within the first year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Nusinersen treatment initiated before 12\u202fmonths of age, especially before 3\u202fmonths of age, yielded the most favorable motor outcomes in patients with SMA type 1. Early initiation is associated with improved motor milestones and reduced need for ventilatory support. However, no significant improvements were observed in the bulbar function or in patients requiring extensive respiratory support.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1541507","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T03:39:18Z","timestamp":1743392358000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Nusinersen for children with type I spinal muscular atrophy: 4\u202fyears\u2019 clinical experience in Turkish cohort"],"prefix":"10.3389","volume":"16","author":[{"given":"\u00d6mer","family":"Bekta\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"G\u00fcl\u015fen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur Burak","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Tekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Y\u00fcksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ercan","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclten","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Salt\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Herg\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe Aysima","family":"\u00d6z\u00e7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilge","family":"\u00d6zg\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Ekici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve Feyza","family":"Y\u00fcksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcleyman","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"Duman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"K\u00f6m\u00fcr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Figen","family":"Baydan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edibe Pembeg\u00fcl","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulu\u00e7","family":"Yi\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Kanmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fcr\u015fat Bora","family":"\u00c7arman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Acar","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Canpolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Sami","family":"G\u00fcven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6k\u00e7en","family":"\u00d6ztuncer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aycan","family":"\u00dcnalp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem","family":"Ard\u0131\u00e7l\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aynur Ay\u015fe","family":"Karaduman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6kmen","family":"Zarars\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclhis","family":"Deda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Turkish SMA Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.3390\/jcm9072222","article-title":"New treatments in spinal muscular atrophy: positive results and new challenges","volume":"9","author":"Messina","year":"2020","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1007\/s10072-020-04365-x","article-title":"SMN1 gene copy number analysis for spinal muscular atrophy (SMA) in a Turkish cohort by CODE-SEQ technology, an integrated solution for detection of SMN1 and SMN2 copy numbers and the \"2+0\" genotype","volume":"41","author":"Ceylan","year":"2020","journal-title":"Neurol Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.ejhg.5200957","article-title":"Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1","volume":"11","author":"Ogino","year":"2003","journal-title":"Eur J Hum Genet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/mus.27380","article-title":"Comparison of the United Kingdom and United States approaches to approval of new neuromuscular therapies","volume":"64","author":"Gallagher","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"CD006281","DOI":"10.1002\/14651858.CD006281.pub5","article-title":"Drug treatment for spinal muscular atrophy type I","volume":"12","author":"Wadman","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"fcac269","DOI":"10.1093\/braincomms\/fcac269","article-title":"Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study","volume":"4","author":"Scheijmans","year":"2022","journal-title":"Brain Commun"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","article-title":"Longitudinal natural history of type I spinal muscular atrophy: a critical review","volume":"15","author":"Mercuri","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Type I SMA \u201cnew natural history\u201d: long-term data in nusinersen-treated patients","volume":"8","author":"Pane","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study","volume":"15","author":"Audic","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejpn.2020.05.002","article-title":"Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: real world data from Hungarian patients","volume":"27","author":"Szab\u00f3","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"117793","DOI":"10.1016\/j.cca.2024.117793","article-title":"Validation of SMA screening kits with SMN1 gene analysis in a Turkish cohort","volume":"555","author":"G\u00fcl\u015fen","year":"2024","journal-title":"Clin Chim Acta"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/ene.15768","article-title":"Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function","volume":"30","author":"Pane","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13023-023-02769-4","article-title":"Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience","volume":"18","author":"\u0141usakowska","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/00207454.2022.2095270","article-title":"Real-world safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 401 Japanese patients: results from an interim analysis of post-marketing surveillance","volume":"134","author":"Tachibana","year":"2024","journal-title":"Int J Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/brain\/awac252","article-title":"Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy","volume":"146","author":"Pechmann","year":"2023","journal-title":"Brain"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/medicina58020213","article-title":"The safety and efficacy of Nusinersen in the treatment of spinal muscular atrophy: a systematic review and Meta-analysis of randomized controlled trials","volume":"58","author":"Abbas","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1152318","DOI":"10.3389\/fped.2023.1152318","article-title":"Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: a systematic review and meta-analysis","volume":"11","author":"Zhong","year":"2023","journal-title":"Front Pediatr"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JND-200533","article-title":"Clinical outcomes in patients with spinal muscular atrophy type 1 treated with Nusinersen","volume":"8","author":"De Holanda","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","article-title":"Respiratory needs in patients with type 1 spinal muscular atrophy treated with Nusinersen","volume":"219","author":"Sansone","year":"2020","journal-title":"J Pediatr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/children9081207","article-title":"Changes in Ventilatory support requirements of spinal muscular atrophy (SMA) patients post gene-based therapies","volume":"9","author":"Panagiotou","year":"2022","journal-title":"Children (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/dmcn.15171","article-title":"Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen","volume":"64","author":"Weststrate","year":"2022","journal-title":"Dev Med Child Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1007\/s00431-024-05735-9","article-title":"Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study","volume":"183","author":"Pane","year":"2024","journal-title":"Eur J Pediatr"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JND-190465","article-title":"Feeding and swallowing problems in infants with spinal muscular atrophy type 1: an observational study","volume":"7","author":"van der Heul","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JND-221667","article-title":"DEVOTE study exploring higher dose of Nusinersen in spinal muscular atrophy: study design and part a results","volume":"10","author":"Finkel","year":"2023","journal-title":"J Neuromuscul Dis"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1541507\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T03:39:23Z","timestamp":1743392363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1541507\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":30,"alternative-id":["10.3389\/fneur.2025.1541507"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1541507","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"article-number":"1541507"}}